kidney cancer Archives
Feb. 17, 2022—Kure It Cancer Research has awarded a $200,000 grant to support kidney cancer research by Vanderbilt's Scott Haake, MD.
May. 24, 2021—A white blood cell, the TREM2/APOE/C1Q-positive macrophage, has been identified as a potential biomarker to predict recurrence of the most common type of kidney cancer and as a possible target for drug development.
Nov. 10, 2020—A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.
May. 10, 2018—W. Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.
Aug. 17, 2017—Vanderbilt-Ingram Cancer Center (VICC) will sponsor an educational conference for kidney cancer patients, survivors and family members Saturday, Sept. 9, 8 a.m. – 2 p.m., in the Preston Research Building, Suite 898.
Sep. 2, 2016—Kidney cancer patients, family members, health care providers and members of the public are invited to attend a free educational workshop about the disease to be held at Vanderbilt-Ingram Cancer Center (VICC).
Aug. 18, 2016—Children, adolescents or young adults, particularly African-Americans, diagnosed with advanced kidney cancer may actually have a rare form of the disease known as renal medullary carcinoma (RMC) that requires a specialized approach and expert intervention.
Apr. 16, 2015—A new study led by Vanderbilt University investigators found that patients being treated with statins at the time of surgery for kidney cancer, also known as renal cell carcinoma, had improved overall survival and disease-specific survival.